CD4+ T cell signaling in the natural SIV host - Implications for disease pathogenesis

Frontiers in Bioscience

Volumn 8, Issue SUPPL., 2003, Pages

  Bostik, Pavel ^a   Dodd, Geraldine L ^a   Ansari, Aftab A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activation; Immune system; Lymphocyte; Review; Signaling; Sooty Mangabey; T cell; T lymphocyte

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

CELL ENERGY; DATA ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DYNAMICS; MONKEY DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS LOAD; ANIMAL; CD4+ T LYMPHOCYTE; CERCOPITHECIDAE; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY; RETROVIRUS; VIROLOGY;

ALPHAVIRUS; CERCOCEBUS TORQUATUS ATYS; HUMAN IMMUNODEFICIENCY VIRUS; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CERCOPITHECIDAE; HUMANS; IMMUNITY, NATURAL; RETROVIRUSES, SIMIAN; SIGNAL TRANSDUCTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 4344630794     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1147     Document Type: Review

References (70)

1. P.N. Fultz, H.M. McClure, D.C. Anderson, R.B. Swenson, R. Anand & A. Srinivasan. Isolation of a T- lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys) Proc Natl Acad Sci U S A 83, 5286-90 (1986)
2. O.M. Diop, A. Gueye, M. Dias-Tavares, C. Kornfeld, A. Faye, P. Ave, M. Huerre, S. Corbet, F. Barre-Sinoussi & M.C. Muller-Trutwin. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 74, 7538-47 (2000)
3. S. Goldstein, I. Ourmanov, C.R. Brown, B.E. Beer, W.R. Elkins, R. Plishka, A. Buckler-White & V.M. Hirsch. Wide range of viral load in healthy african green monkeys naturally infected with simian immunodeficiency virus. J Virol 74, 11744-53 (2000)
4. S. Holzammer, E. Holznagel, A. Kaul, R. Kurth & S. Norley. High virus loads in naturally and experimentally SIVagm-infected African green monkeys. Virology 283, 324-31 (2001)
5. J. Ennen, H. Findeklee, M.T. Dittmar, S. Norley, M. Ernst & R. Kurth. CD8+ T lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc Natl Acad Sci U S A 91, 7207-11 (1994)
6. L.A. Chakrabarti, S.R. Lewin, L. Zhang, A. Gettie, A. Luckay, L.N. Martin, E. Skulsky, D.D. Ho, C. Cheng-Mayer & P.A. Marx. Age-dependent changes in T cell homeostasis and SIV load in sooty mangabeys. J Med Primatol 29, 158-65 (2000)
7. L.A. Chakrabarti, S.R. Lewin, L. Zhang, A. Gettie, A. Luckay, L.N. Martin, E. Skulsky, D.D. Ho, C. Cheng-Mayer & P.A. Marx. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J. Virol. 74, 1209-1223 (2000)
8. A. Ahmed-Ansari, A.R. Brodie, P.N. Fultz, D. Anderson, K.W. Sell & H.M. McClure. Flow microfluorometric analysis of peripheral blood mononuclear cells from nonhuman primates: Correlation of phenotype with immune function. Am J Primatol 17, 107-131 (1989)
9. R.J. De Boer, H. Mohri, D.D. Ho & A.S. Perelson. Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol 170, 2479-87 (2003)
10. C.D. Belair, T.R. Yeager, P.M. Lopez & C.A. Reznikoff. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U.S.A. 94, 13677-13682 (1997)
11. K. Hiyama, Y. Hirai, S. Kyoizumi, M. Akiyama, E. Hiyama, M.A. Piatyszek, J.W. Shay, S. Ishioka & M. Yamakido. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155, 3711-3715 (1995)
12. N.P. Weng, B.L. Levine, C.H. June & R.J. Hodes. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 183, 2471-2479 (1996)
13. R.C. Allsopp, S. Cheshier & I.L. Weissman. Telomerase activation and rejuvenation of telomere length in stimulated T cells derived from serially transplanted hematopoietic stem cells. J Exp Med 196, 1427-33 (2002)
14. P. Bostik, G.T. Brice, K.P. Greenberg, A.E. Mayne, F. Villinger, M.G. Lewis & A.A. Ansari. Inverse correlation of telomerase activity/ proliferation of CD4+ T lymphocytes and disease progression in simian immunodeficiency virus-infected nonhuman primates. J Acquir Immune Defic Syndr 24, 89-99 (2000)
15. M.T. Roos, M. Prins, M. Koot, F. de Wolf, M. Bakker, R.A. Coutinho, F. Miedema & P.T. Schellekens. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. Aids 12, 1745-51 (1998)
16. P.T. Schellekens, M.T. Roos, F. De Wolf, J.M. Lange & F. Miedema. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HlV-1)-infected men. J Clin Immunol 10, 121-7 (1990)
17. I. Stefanova, M.W. Saville, C. Peters, F.R. Cleghorn, D. Schwartz, D.J. Venzon, K.J. Weinhold, N. Jack, C. Bartholomew, W.A. Blattner, R. Yarchoan, J.B. Bolen & I.D. Horak. HIV infection - induced posttranslational modification of T cell signaling molecules associated with disease progression. J.Clin.Invest. 98, 1290-1297 (1996)
18. M.J. Gale, Jr., J.A. Ledbetter, G.L. Schieven, M. Jonker, W.R. Morton, R.E. Benveniste & E.A. Clark. CD4 and CD8 T cells from SIV-infected macaques have defective signaling responses after perturbation of either CD3 or CD2 receptors. Int.Immunol. 2, 849-858 (1990)
19. I.D. Horak, M. Popovic, E.M. Horak, P.J. Lucas, R.E. Gress, C.H. June & J.B. Bolen. No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120. Nature 348, 557-560 (1990)
20. S.B. Kanner & O.K. Haffar. HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p561ck dissociation. J.Immunol. 154, 2996-3005 (1995)
21. D. Cefai, M. Ferrer, N. Serpente, T. Idziorek, A. Dautry-Varsat, P. Debre & G. Bismuth. Internalization of HIV glycoprotein gp120 is associated with down- modulation of membrane CD4 and p561ck together with impairment of T cell activation. J Immunol 149, 285-294 (1992)
22. P. Hubert, G. Bismuth, M. Korner & P. Debre. HIV-1 glycoprotein gp120 disrupts CD4-p561ck/CD3-T cell receptor interactions and inhibits CD3 signaling. Eur.J.Immunol. 25, 1417-1425 (1995)
23. H. Schmid-Antomarchi, M. Benkirane, V. Breittmayer, H. Husson, M. Ticchioni, C. Devaux & B. Rossi. HIV induces activation of phosphatidylinositol 4-kinase and mitogen-activated protein kinase by interacting with T cell CD4 surface molecules. Eur.J.Immunol. 26, 717-720 (1996)
24. L. Briant, V. Robert-Hebmann, V. Sivan, A. Brunet, J. Pouyssegur & C. Devaux. Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappa B and AP-1 transcription factors. J Immunol 160, 1875-85 (1998)
25. A.Y. Howe, J.U. Jung & R.C. Desrosiers. Zeta chain of the T-cell receptor interacts with nef of simian immunodeficiency virus and human immunodeficiency virus type 2. J.Virol. 72, 9827-9834 (1998)
26. Y. Collette, H. Dutartre, A. Benziane, Ramos-Morales, R. Benarous, M. Harris & D. Olive. Physical and functional interaction of Nef with Lck. HIV-1 Nef-induced T-cell signaling defects. J.Biol.Chem. 271, 6333-6341 (1996)
27. W. Luo & B.M. Peterlin. Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus. J.Virol. 71, 9531-9537 (1997)
28. S. Sabbaj, M.F. Para, R.J. Pass, P.W. Adams, C.G. Orosz & C.C. Whitacre. Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis. J Clin Immunol 12, 216-24 (1992)
29. P. Foley, F. Kazazi, R. Biti, T.C. Sorrell & A.L. Cunningham. HIV infection of monocytes inhibits the T-lymphocyte proliferative response to recall antigens, via production of eicosanoids. Immunology 75, 391-7 (1992)
30. C.L. Ruegg & E.G. Engleman. Impaired immunity in AIDS. The mechanisms responsible and their potential reversal by antiviral therapy. Ann N Y Acad Sci 616, 307-17 (1990)
31. V.J. Teeuwsen, K.H. Siebelink, F. de Wolf, J. Goudsmit, F.G. UytdeHaag & A.D. Osterhaus. Impairment of in vitro immune responses occurs within 3 months after HIV-1 seroconversion. AIDS 4, 77-81 (1990)
32. P. Bostik, A.E. Mayne, F. Villinger, K.P. Greenberg, J.D. Powell & A.A. Ansari. Relative Resistance in the Development of T Cell Anergy in CD4(+) T Cells from Simian Immunodeficiency Virus Disease-Resistant Sooty Mangabeys. J Immunol 166, 506-516 (2001)
33. P. Bostik, P. Wu, G.L. Dodd, F. Villinger, A.E. Mayne, V. Bostik, B.D. Grimm, D. Robinson, H.J. Kung & A.A. Ansari. Identification of Protein Kinases Dysregulated in CD4(+) T Cells in Pathogenic versus Apathogenic Simian Immunodeficiency Virus Infection. J Virol 75, 11298-306. (2001)
34. O.T. Fackler, W. Luo, M. Geyer, A.S. Alberts & B.M. Peterlin. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell 3, 729-39 (1999)
35. X. Lu, X. Wu, A. Plemenitas, H. Yu, E.T. Sawai, A. Abo & B.M. Peterlin. CDC42 and Rac1 are implicated in the activation of the Nef-associated kinase and replication of HIV-1. Curr Biol 6, 1677-84 (1996)
36. D. Cantrell. Lymphocyte signalling: a coordinating role for Vav? Curr Biol 8, R535-8 (1998)
37. K. Bachmaier, C. Krawczyk, I. Kozieradzki, Y.Y. Kong, T. Sasaki, A. Oliveira-dos-Santos, S. Mariathasan, D. Bouchard, A. Wakeham, A. Itie, J. Le, P.S. Ohashi, I. Sarosi, H. Nishina, S. Lipkowitz & J.M. Penninger. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403, 211-6 (2000)
38. Y.J. Chiang, H.K. Kole, K. Brown, M. Naramura, S. Fukuhara, R.J. Hu, I.K. Jang, J.S. Gutkind, E. Shevach & H. Gu. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403, 216-20 (2000)
39. M. Clerici, M. Galli, S. Bosis, C. Gervasoni, M. Moroni & G. Norbiato. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann N Y Acad Sci 917, 956-61 (2000)
40. A.A. Ansari, A. Mayne, D. Hunt, J.B. Sundstrom & F. Villinger. TH1/TH2 subset analysis. I. Establishment of criteria for subset identification in PBMC samples from nonhuman primates. J Med Primatol 23, 102-7 (1994)
41. S.G. Rane & E.P. Reddy. Janus kinases: components of multiple signaling pathways. Oncogene 19, 5662-79 (2000)
42. W.J. Leonard & J.J. O'Shea. Jaks and STATs: biological implications. Annual Review of Immunology 16, 293-322 (1998)
43. F. Pericle, L.A. Pinto, S. Hicks, R.A. Kirken, G. Sconocchia, J. Rusnak, M.J. Dolan, G.M. Shearer & D.M. Segal. HIV-1 infection induces a selective reduction in STAT5 protein expression. Journal of Immunology 160, 28-31 (1998)
44. C. Bovolenta, L. Camorali, A.L. Lorini, S. Ghezzi, E. Vicenzi, A. Lazzarin & G. Poli. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 94, 4202-9 (1999)
45. M. Federico, Z. Percario, E. Olivetta, G. Fiorucci, C. Muratori, A. Micheli, G. Romeo & E. Affabris. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 98, 2752-61 (2001)
46. J.J. Kohler, D.L. Tuttle, C.R. Coberley, J.W. Sleasman & M.M. Goodenow. Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD4(+) cells of lymphocyte or monocyte/macrophage lineages. J Leukoc Biol 73, 407-16 (2003)
47. M.H. Kaplan, U. Schindler, S.T. Smiley & M.J. Grusby. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4, 313-9 (1996)
48. M.K. Jenkins & R.H. Schwartz. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165, 302-19 (1987)
49. R.H. Schwartz. T cell clonal anergy. Curr Opin Immunol 9, 351-7 (1997)
50. L.S. Davis & P.E. Lipsky. Tolerance induction of human CD4+ T cells: markedly enhanced sensitivity of memory versus naive T cells to peripheral anergy. Cell Immunol 146, 351-61 (1993)
51. C.C. Maier & M.I. Greene. Biochemical features of anergic T cells. Immunol Res 17, 133-40 (1998)
52. M. Carlesimo, M.L. Bernardi, G. Mattiacci, M. Pierdominici, R. Ferrara, S. Donnanno, C. Alario & F. Aiuti. Evaluation of T-cell response to CD3 plus CD28 monoclonal antibodies in HIV-1 infected subjects treated with highly active antiretroviral therapy. J Biol Regul Homeost Agents 14, 38-40 (2000)
53. B. Autran, G. Carcelain, T.S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre & J. Leibowitch. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116 (1997)
54. F.P. Kroon, G.F. Rimmelzwaan, M.T. Roos, A.D. Osterhaus, D. Hamann, F. Miedema & J.T. van Dissel. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 12, F217-23 (1998)
55. L. Weiss, P. Ancuta, P.M. Girard, H. Bouhlal, A. Roux, N.H. Cavaillon & M.D. Kazatchkine. Restoration of normal interleukin-2 production by CD4+ T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy. J Infect Dis 180, 1057-63 (1999)
56. M. Dybul, G. Mercier, M. Belson, C.W. Hallahan, S. Liu, C. Perry, B. Herpin, L. Ehler, R.T. Davey, J.A. Metcalf, J.M. Mican, R.A. Seder & A.S. Fauci. CD40 ligand trimer and IL-12 enhance peripheral blood mononuclear cells and CD4+ T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness. J Immunol 165, 1685-91 (2000)
57. N. Jabado, A. Pallier, S. Jauliac, A. Fischer & C. Hivroz. gp160 of HIV or anti-CD4 monoclonal antibody ligation of CD4 induces inhibition of JNK and ERK-2 activities in human peripheral CD4+ T lymphocytes. Eur. J Immunol 27, 397-404 (1997)
58. S. Jauliac, F. Mazerolles, N. Jabado, A. Pallier, F. Bernard, J. Peake, A. Fischer & C. Hivroz. Ligands of CD4 inhibit the association of phospholipase Cgammal with phosphoinositide 3 kinase in T cells: regulation of this association by the phosphoinositide 3 kinase activity. Eur J Immunol 28, 3183-91 (1998)
59. M. Clerici, C. Balotta, L. Meroni, E. Ferrario, C. Riva, D. Trabattoni, A. Ridolfo, M. Villa, G.M. Shearer, M. Moroni & M. Galli. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res Hum Retroviruses 12, 1053-61 (1996)
60. P. An, M.P. Martin, G.W. Nelson, M. Carrington, M.W. Smith, K. Gong, D. Vlahov, S.J. O'Brien & C.A. Winkler. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans [In Process Citation]. Aids 14, 2117-22 (2000)
61. M.P. Martin, M. Dean, M.W. Smith, C. Winkler, B. Gerrard, N.L. Michael, B. Lee, R.W. Doms, J. Margolick, S. Buchbinder, J.J. Goedert, T.R. O'Brien, M.W. Hilgartner, D. Vlahov, S.J. O'Brien & M. Carrington. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282, 1907-11 (1998)
62. A.O. Clegg, L.J. Ashton, R.A. Biti, P. Badhwar, P. Williamson, J.M. Kaldor & G.J. Stewart. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. Aids 14, 103-8 (2000)
63. D.H. McDermott, P.A. Zimmerman, F. Guignard, C.A. Kleeberger, S.F. Leitman & P.M. Murphy. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS) Lancet 352, 866-70 (1998)
64. H. Liu, D. Chao, E.E. Nakayama, H. Taguchi, M. Goto, X. Xin, J.K. Takamatsu, H. Saito, Y. Ishikawa, T. Akaza, T. Juji, Y. Takebe, T. Ohishi, K. Fukutake, Y. Maruyama, S. Yashiki, S. Sonoda, T. Nakamura, Y. Nagai, A. Iwamoto & T. Shioda. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 96, 4581-5 (1999)
65. M.W. Quasney, Q. Zhang, S. Sargent, M. Mynatt, J. Glass & J. McArthur. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 50, 157-62 (2001)
66. B.M. Brinkman, I.P. Keet, F. Miedema, C.L. Verweij & M.R. Klein. Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons. J Infect Dis 175, 188-90 (1997)
67. M.C. Knuchel, T.J. Spira, A.U. Neumann, L. Xiao, D.L. Rudolph, J. Phair, S.M. Wolinsky, R.A. Koup, O.J. Cohen, T.M. Folks & R.B. Lal. Analysis of a biallelic polymorphism in the tumor necrosis factor alpha promoter and HIV type 1 disease progression. AIDS Res Hum Retroviruses 14, 305-9 (1998)
68. J.H. Bream, M. Carrington, S. O'Toole, M. Dean, B. Gerrard, H.D. Shin, D. Kosack, W. Modi, H.A. Young & M.W. Smith. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 51, 50-8 (2000)
69. E.E. Nakayama, Y. Hoshino, X. Xin, H. Liu, M. Goto, N. Watanabe, H. Taguchi, A. Hitani, A. Kawana-Tachikawa, M. Fukushima, K. Yamada, W. Sugiura, S.I. Oka, A. Ajisawa, H. Sato, Y. Takebe, T. Nakamura, Y. Nagai, A. Iwamoto & T. Shioda. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 74, 5452-9 (2000)
70. S. Kitagawa-Sakakida & R.H. Schwartz. Multifactor cis-dominant negative regulation of IL-2 gene expression in anergized T cells. J Immunol 157, 2328-39 (1996)